| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JTK10; THCYT3 |
| Entrez GeneID | 3717 |
| clone | 5C12C9 |
| WB Predicted band size | 130.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human JAK2 (AA: 745-955) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于JAK2抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**：*JAK2 V617F Mutation in Myeloproliferative Disorders: Diagnostic Utility and Comparison with Other Genetic Markers*
**作者**：Baxter EJ, et al.
**期刊**：*The Lancet* (2005)
**摘要**：该研究首次证实JAK2 V617F突变在真性红细胞增多症(PV)、原发性血小板增多症(ET)和骨髓纤维化(PMF)中的高发生率。研究通过基因测序和抗体检测(如Western blot)验证了突变导致JAK2蛋白持续激活，为疾病诊断提供了关键分子标志物。
2. **文献名称**：*The Role of JAK2 Antibodies in the Diagnosis of Chronic Myeloproliferative Neoplasms*
**作者**：Tefferi A, Vardiman JW
**期刊**：*Blood* (2008)
**摘要**：综述总结了JAK2突变检测在骨髓增殖性肿瘤(MPN)中的临床意义，强调基于JAK2抗体的免疫分析(如ELISA或免疫组化)与分子检测(如PCR)的结合应用，可提高诊断特异性，并指导靶向治疗策略。
3. **文献名称**：*Development of a Monoclonal Antibody for Specific Detection of JAK2 Phosphorylation in Myelofibrosis*
**作者**：Levine RL, et al.
**期刊**：*Blood* (2007)
**摘要**：研究团队开发了一种高特异性的抗磷酸化JAK2抗体，用于检测骨髓纤维化患者中JAK2信号通路的异常激活。该抗体在体外实验和患者样本中均表现出高灵敏性，为疾病机制研究和治疗反应监测提供了工具。
---
以上文献涵盖了JAK2抗体在突变检测、诊断应用及信号通路研究中的关键作用。如需扩展，可进一步探讨JAK2靶向治疗或抗体技术优化的研究。
The Janus kinase 2 (JAK2) protein is a tyrosine kinase critical for signaling pathways regulating hematopoiesis, immune responses, and cell growth. It mediates cytokine receptor signaling through the JAK-STAT pathway, activating transcription factors that drive gene expression. JAK2 gained clinical significance due to its association with myeloproliferative neoplasms (MPNs). A somatic mutation (V617F) in the JAK2 gene, causing constitutive kinase activation, is found in >95% of polycythemia vera cases and 50-60% of essential thrombocythemia and primary myelofibrosis cases.
JAK2 antibodies are essential tools in research and diagnostics. They enable detection of JAK2 expression, phosphorylation status, and mutation-specific epitopes (e.g., V617F) via techniques like immunohistochemistry (IHC), Western blotting, or ELISA. Clinically, these antibodies aid in diagnosing MPNs by identifying mutant JAK2 in bone marrow or blood samples. Additionally, they support drug development targeting hyperactive JAK2. such as JAK inhibitors (e.g., ruxolitinib), which alleviate MPN symptoms by suppressing aberrant signaling. However, wild-type JAK2's role in normal hematopoiesis necessitates careful therapeutic targeting to avoid off-target effects. Research continues to explore JAK2's broader implications in autoimmune diseases and cancer.
×
